Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...

2 月 26日，阿斯利康宣布SERENA-6 III 期临床试验中， Camizestrant 在一线晚期 HR 阳性乳腺癌（伴 ESR1 肿瘤突变）患者中表现出高度统计学显著和临床意义的 ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

▎药明康德内容团队编辑阿斯利康（AstraZeneca）公司今日宣布，3期临床试验SERENA-6的中期分析显示，其在研口服选择性雌激素受体降解剂（SERD）camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期（PFS）上显示出统 ...

AstraZeneca's new therapy, camizestrant, shows promising results in improving survival rates for patients with advanced ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.